ReviewBMC medicine2013
Depression pathogenesis and treatment: what can we learn from blood mRNA expression?
Review in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Changes in RNA expression levels during antidepressant treatment: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2021Pooled it
- Genetic Contributions of Inflammation to Depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Pooled it
- Effects of Cortisol Administration on Resting-State Functional Connectivity in Women with Depression.Psychiatry research. Neuroimaging · 2024Trial
- MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.Nature communications · 2017Trial
- Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients.The international journal of neuropsychopharmacology · 2016Trial
- Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.Brain, behavior, and immunity · 2013Trial
- Epigenetic, neuroplasticity, and adrenergic targets associated with major depression in immune cells.Scientific reports · 2026Article
- Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.Molecular psychiatry · 2025Review
- Cardiovascular disease and depression: a bidirectional relationship and its clinical implications.Frontiers in psychiatry · 2025Review
- Integrative Analysis of the Impact of Prenatal Depression on the Newborn Intestinal Microbiota.Central nervous system agents in medicinal chemistry · 2025Article
- Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov.Translational psychiatry · 2024Review
- Exploring the Potential Molecular Mechanism of the Shugan Jieyu Capsule in the Treatment of Depression through Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.Current computer-aided drug design · 2024Article
- Identification and experimental validation of hub genes underlying depressive-like behaviors induced by chronic social defeat stress.Frontiers in pharmacology · 2024Article
- Higher immune-related gene expression in major depression is independent of CRP levels: results from the BIODEP study.Translational psychiatry · 2023Article
- Co-expression network of mRNA and DNA methylation in first-episode and drug-naive adolescents with major depressive disorder.Frontiers in psychiatry · 2023Article
- Article
- Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients.Journal of personalized medicine · 2022Article
- Screening of SERT and p11 mRNA Levels in Airline Pilots: A Translational Approach.Frontiers in psychiatry · 2022Article
- Preventive strategies for adolescent depression: What are we missing? A focus on biomarkers.Brain, behavior, & immunity - health · 2021Article
- Highlighting Immune System and Stress in Major Depressive Disorder, Parkinson's, and Alzheimer's Diseases, with a Connection with Serotonin.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alterations in several biological systems, including the neuroendocrine and immune systems, have been consistently demonstrated in patients with major depressive disorder. These alterations have been predominantly studied using easily accessible systems such as blood and saliva. In recent years there has been an increasing body of evidence supporting the use of peripheral blood gene expression to investigate the pathogenesis of depression, and to identify relevant biomarkers. In this paper we review the current literature on gene expression alterations in depression, focusing in particular on three important and interlinked biological domains: inflammation, glucocorticoid receptor functionality and neuroplasticity. We also briefly review the few existing transcriptomics studies. Our review summarizes data showing that patients with major depressive disorder exhibit an altered pattern of expression in several genes belonging to these three biological domains when compared with healthy controls. In particular, we show evidence for a pattern of 'state-related' gene expression changes that are normalized either by remission or by antidepressant treatment. Taken together, these findings highlight the use of peripheral blood gene expression as a clinically relevant biomarker approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.